Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type

Journal of Pathology - Tập 238 Số 3 - Trang 389-400 - 2016
Anthony N. Karnezis1, Yemin Wang1, Pilar Ramos2, William P.D. Hendricks2, Esther Oliva3, Emanuela D’Angelo4, Jaime Prat4, Marisa R. Nucci5, Torsten O. Nielsen1, Christine Chow6, Samuel Leung6, Friedrich Kommoss7, Stefan Kommoss8, Annacarolina da Silva9, Brigitte M. Ronnett10, Joseph T. Rabban11, David D.L. Bowtell12, Bernard E. Weissman13, Jeffrey M. Trent2, C. Blake Gilks1, David G. Huntsman14,1,6
1Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada
2Division of Integrated Cancer Genomics, Translational Genomics Research Institute (TGen), Phoenix, AZ, USA
3Department of Pathology, Massachusetts General Hospital, Boston, MA, USA
4Department of Pathology, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain
5Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA
6Genetic Pathology Evaluation Centre, Vancouver General Hospital, University of British Columbia, Vancouver, BC, Canada
7Synlab MVZ Pathologie, Mannheim, Germany
8Department of Obstetrics and Gynecology, University Hospital of Tuebingen, Tuebingen, Germany
9The James Homer Wright Pathology Laboratories, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
10Department of Pathology, The Johns Hopkins Hospital, Baltimore, MD, USA
11Department of Anatomic Pathology, University of California San Francisco, San Francisco, CA, USA
12Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
13Department of Pathology and Laboratory Medicine, Lineberger Cancer Center, University of North Carolina, Chapel Hill, NC, USA
14Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, BC, Canada

Tóm tắt

AbstractSmall cell carcinoma of the ovary, hypercalcaemic type (SCCOHT) is a lethal and sometimes familial ovarian tumour of young women and children. We and others recently discovered that over 90% of SCCOHTs harbour inactivating mutations in the chromatin remodelling gene SMARCA4 with concomitant loss of its encoded protein SMARCA4 (BRG1), one of two mutually exclusive ATPases of the SWI/SNF chromatin remodelling complex. To determine the specificity of SMARCA4 loss for SCCOHT, we examined the expression of SMARCA4 by immunohistochemistry in more than 3000 primary gynaecological tumours. Among ovarian tumours, it was only absent in clear cell carcinoma (15 of 360, 4%). In the uterus, it was absent in endometrial stromal sarcomas (4 of 52, 8%) and high‐grade endometrioid carcinomas (2 of 338, 1%). Recent studies have shown that SMARCA2 (BRM), the other mutually exclusive ATPase of the SWI/SNF complex, is necessary for survival of tumour cells lacking SMARCA4. Therefore, we examined SMARCA2 expression and discovered that all SMARCA4‐negative SCCOHTs also lacked SMARCA2 protein by IHC, including the SCCOHT cell lines BIN67 and SCCOHT1. Among ovarian tumours, the SMARCA4/SMARCA2 dual loss phenotype appears completely specific for SCCOHT. SMARCA2 loss was not due to mutation but rather from an absence of mRNA expression, which was restored by treatment with the histone deacetylase inhibitor trichostatin A. Re‐expression of SMARCA4 or SMARCA2 inhibited the growth of BIN67 and SCCOHT1 cell lines. Our results indicate that SMARCA4 loss, either alone or with SMARCA2, is highly sensitive and specific for SCCOHT and that restoration of either SWI/SNF ATPase can inhibit the growth of SCCOHT cell lines. © 2015 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.

Từ khóa


Tài liệu tham khảo

10.1097/00000478-199411000-00004

10.1038/ng.2928

10.1038/ng.2931

10.5114/pjp.2013.39331

10.1038/ng.2922

10.1038/cr.2011.32

10.1093/genetics/108.4.845

10.1016/0022-2836(84)90315-2

10.1038/ng.2628

10.1371/journal.pone.0055119

10.1158/0008-5472.CAN-12-4593

10.1073/pnas.1316793111

10.1016/j.ccr.2014.07.018

10.1038/modpathol.3800950

10.4161/2167549X.2014.967148

10.1097/01.pgp.0000183048.22588.18

10.1038/sj.onc.1205188

10.1074/jbc.M009747200

10.1074/jbc.M109532200

10.1158/0008-5472.CAN-07-2601

10.1158/0008-5472.CAN-04-3554

10.1371/annotation/856f0890-9d85-4719-8e54-c27530ac94f4

10.1016/0092-8674(94)90405-7

10.1093/emboj/17.1.223

10.1128/MCB.16.4.1576

10.1073/pnas.97.14.7748

10.1002/path.4225

10.1038/modpathol.3800687

10.1111/j.1365-2559.2007.02790.x

10.1097/00000478-199101000-00003

10.1126/scisignal.2004088

10.1158/2159-8290.CD-12-0095

10.1038/nature10166

10.1002/path.4230

10.1128/MCB.01372-13

Reisman DN, 2003, Loss of BRG1/BRM in human lung cancer cell lines and primary lung cancers: correlation with poor prognosis, Cancer Res, 63, 560

10.1111/cas.12065

10.1038/modpathol.2013.216

10.1097/PAP.0000000000000038

10.1097/PAS.0b013e31824a7b1a

10.18632/oncotarget.1945

10.1016/j.humpath.2014.06.027

10.1038/sj.onc.1208716

10.1002/path.4362